IRMD icon

iRadimed

52.82 USD
+0.73
1.40%
Updated Apr 23, 1:16 PM EDT
1 day
1.40%
5 days
1.67%
1 month
-0.08%
3 months
-12.46%
6 months
4.61%
Year to date
-3.86%
1 year
26.06%
5 years
157.41%
10 years
234.30%
 

About: iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Employees: 160

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

209% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 11

69% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 39

14% more funds holding

Funds holding: 143 [Q3] → 163 (+20) [Q4]

12% more capital invested

Capital invested by funds: $339M [Q3] → $381M (+$42.3M) [Q4]

1.46% more ownership

Funds ownership: 53.24% [Q3] → 54.7% (+1.46%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

81% less call options, than puts

Call options by funds: $33K | Put options by funds: $176K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$72
36%
upside
Avg. target
$72
36%
upside
High target
$72
36%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Roth MKM
Jason Wittes
35% 1-year accuracy
7 / 20 met price target
36%upside
$72
Buy
Reiterated
14 Feb 2025

Financial journalist opinion

Positive
Seeking Alpha
2 weeks ago
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space
IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets.
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference.
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
Neutral
Seeking Alpha
2 months ago
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
IRadimed (IRMD) Lags Q4 Earnings Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago.
IRadimed (IRMD) Lags Q4 Earnings Estimates
Neutral
GlobeNewsWire
2 months ago
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
Neutral
GlobeNewsWire
3 months ago
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024.
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
Positive
Zacks Investment Research
3 months ago
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
Neutral
GlobeNewsWire
4 months ago
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference.
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Zacks Investment Research
4 months ago
Here's Why Momentum in iRadimed (IRMD) Should Keep going
iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in iRadimed (IRMD) Should Keep going
Neutral
GlobeNewsWire
4 months ago
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
Charts implemented using Lightweight Charts™